Editorial

Transformative advancements in breast cancer treatment

Volume 12 Issue 4 - 2024

Jagadish Hansa
Scientific Officer, Sona Thesis Consultancy, India

Correspondence: Jagadish Hansa, Scientific Officer, Sona Thesis Consultancy, India, Tel +91 9304786310, Email jagadish.hansa@gmail.com

Received: December 16, 2024 | **Published:** December 19, 2024

Editorial

Breast cancer has remained a significant health burden globally, but contemporary research is reshaping the treatment paradigm, offering new hope to patients. The integration of precision medicine, immunotherapy, and advanced technologies exemplifies the innovative strides in the field.[1,2]

Precision medicine: a game-changer

Targeted therapies have revolutionized breast cancer management, especially in HER2-positive cases, where drugs like Trastuzumab have dramatically improved outcomes.[3] Similarly, BRCA1/2 mutation carriers have benefitted from PARP inhibitors, showcasing the impact of genetic profiling.[4]

Immunotherapy: harnessing the body's defense

Immunotherapy has shown promise, particularly in triple-negative breast cancer (TNBC). The efficacy of immune checkpoint inhibitors such as Pembrolizumab has been demonstrated in clinical trials, providing an essential treatment option for TNBC patients.[5]

Advances in early detection and prevention

Advances in genetic testing and liquid biopsies, including circulating tumor DNA (ctDNA) detection, allow early intervention.[6] Risk-reducing strategies, like prophylactic mastectomy in high-risk individuals, further underscore the importance of early detection.[7] Genetic screening of BRCA1/2 to the family effected with breast cancer.[8]

Minimally invasive and adaptive therapies

Minimally invasive surgeries, such as sentinel lymph node biopsy, have become standard, reducing morbidity while ensuring effective treatment.[9] Adaptive radiotherapy, guided by AI, minimizes radiation exposure to healthy tissues, enhancing patient outcomes.[10]

AI and big data in breast cancer research

AI applications in diagnostics and treatment planning have improved accuracy and individualized care.[11] Machine learning algorithms analyzing imaging data have enhanced early detection and reduced diagnostic errors.[12]

Hope for the future: ongoing clinical trials

Innovative treatments, including antibody-drug conjugates (ADCs), are advancing rapidly. The approval of Sacituzumab Govitecan highlights the potential of novel therapeutics in metastatic TNBC.[13]

Patient-centered care

Patient-centered care is now a cornerstone of breast cancer management, with survivorship programs and psychological support playing critical roles in improving quality of life.[14–16]

Conclusion

Today's advancements underscore the power of collaboration and innovation in breast cancer research. Continued investment in research and technology promises a brighter future for patients worldwide.

Acknowledgments

None.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. *CA Cancer J Clin*. 2023;73(1):17–48.
2. Ginsburg OM, Hanna TP, Fitzal F. Breast cancer early detection: a decade of progress. *Lancet Oncol*. 2022;23(3):e108–e118.
3. Giordano SH, Elias A, Gradishar WJ. HER2-targeted therapies in breast cancer: current practice and future perspectives. *J Clin Oncol*. 2022;40(1):1–12.

4. Tutt AN, Garber JE, Kaufman B. OlympiAD: Long-term efficacy of PARP inhibitors in BRCA-mutated breast cancer. *N Engl J Med*. 2021;384(25):2394–405.

5. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108-2121.

6. Rosenberg SM, Partridge AH. Genetic testing for breast cancer: current challenges and opportunities. *JAMA Oncol*. 2021;7(9):1317–1325.

7. Domchek SM, Lin F, Allen B. Risk-reducing mastectomy in BRCA mutation carriers: outcomes and patient perspectives. *Breast Cancer Res Treat*. 2020;183(1):1–11.

8. Hansa J, Kannan R, Ghosh SK. Screening of 185DelAG, 1014DelGT and 3889DelAG BRCA1 mutations in breast cancer patients from North-East India. *Asian Pac J Cancer Prev*. 2012;13(11):5871–5874.

9. Van der Ploeg IM, Nieweg OE, Kroon BB. The sentinel node procedure in breast cancer: historical and current perspectives. *Eur J Surg Oncol*. 2022;48(1):1–9.

10. Haffty BG, Freedman G, Harris EE. Adaptive radiotherapy in breast cancer: redefining precision. *J Clin Oncol*. 2021;39(18):2001–2011.

11. Hansa J. Can AI help breast cancer research? *Hematol Tranfus Int*. 2024;12(3);73–75.

12. Yala A, Mikhael PG, Strandburg L. Deep learning for breast cancer screening: comparative study with radiologists. *Radiology*. 2020;296(3):456–465.

13. Bardia A, Mayer IA, Diamond JR, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. *N Engl J Med*. 2021;384(16):1529–1541.

14. Burstein HJ, Krilov L, Aragon-Ching JB. Patient-centered cancer care: Frameworks and implementation. *J Clin Oncol*. 2021;39(12):1361–8.

15. McLaughlin S, Barrett A, Kerin MJ. Genomics and breast cancer care: Integration into clinical practice. *Breast Cancer Res*. 2021;23(1):15–25.

16. Banerjee S, Basu S, Banerjee A. Breast cancer treatment in low-resource settings: Challenges and solutions. *Lancet Oncol*. 2021;22(9):e396–406.

Citation: Hansa J. Transformative advancements in breast cancer treatment. *Hematol Transfus Int.* 2024;12(4):100–101. DOI: 10.15406/htij.2024.12.00342